Ruben Mesa
Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Mays Cancer Center at UT Health San Antonio MD Anderson · Mays Cancer Center at UT Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ruben Mesa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07447817 · Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasJohn Mascarenhas · recruiting · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- N/ANCT04345952 · Calm for Cancer Patients Receiving ChemotherapyThe University of Texas Health Science Center at San Antonio · withdrawn · Cancer Colorectal · principal investigator
- Ph2NCT04281498 · Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationJohn Mascarenhas · completed · Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation · study chair
- Ph3NCT04173494 · A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)Sierra Oncology LLC - a GSK company · completed · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · principal investigator
- Ph1NCT03895112 · MPN-RC 118 AVID200 in MyelofibrosisJohn Mascarenhas · completed · Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis · study chair
- Ph2NCT01732445 · Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With MyelofibrosisMayo Clinic · completed · Anemia, Primary Myelofibrosis, Secondary Myelofibrosis · principal investigator
- Ph3NCT01259856 · Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · study chair
- Ph1/Ph2NCT00745550 · A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisS*BIO · completed · Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera · principal investigator
- Ph2NCT00047190 · Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaNational Cancer Institute (NCI) · completed · Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Prevention and Control Research ProgramP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2022 to 2026 · $33,502 awarded in 2026Same name and institution; not confirmed by an ID
- Apoptosis in myelofibrosis with myeloid metaplasiaK23CA096780 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2002 to 2006 · $124,075 awarded in 2006Same name and institution; not confirmed by an ID
- TRUNCATED C-ERBB RECEPTORS IN OVARIAN CARCINOMASF31CA060353 · NCI · MAYO CLINIC ROCHESTER · fiscal years 1992 · $9,933 awarded in 1992Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3: Development of Strategies to Deplete Myelofibrosis Stem CellsP01CA108671 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ronald Hoffman · fiscal years 2014 to 2026
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2014 to 2026Named on NCT01732445
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:04 UTC. The ranking covers the 200 most relevant of 103 PubMed records, and a shared surname and initials can bring in a namesake. All 103 on PubMed
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med · 20121,769 citationsRCR 44.2
- 991 citationsRCR 21.4
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera.N Engl J Med · 2015680 citationsRCR 21.0
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol · 2015429 citationsRCR 12.6
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.J Hematol Oncol · 2017366 citationsRCR 12.4
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol · 2018355 citationsRCR 11.4
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.J Clin Oncol · 2017336 citationsRCR 10.1
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.Lancet Haematol · 2017294 citationsRCR 9.3
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.Lancet Haematol · 2017289 citationsRCR 8.8
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.J Hematol Oncol · 2017255 citationsRCR 8.5